2hon MSN
Vistagen targets NDA submission for fasedienol in mid-2026 as PALISADE-3 study nears data readout
Get the latest on Vistagen Therapeutics' Q2 2026 earnings, PALISADE-3 trial milestones, and upcoming fasedienol data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback